Bioxcel therapeutics to participate at the canaccord genuity 42nd annual growth conference

New haven, conn., aug. 03, 2022 (globe newswire) -- bioxcel therapeutics, inc. (nasdaq: btai), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that vimal mehta, ph.d., founder and chief executive officer, and matt wiley, chief commercial officer, will participate in a fireside chat at the canaccord genuity 42nd annual growth conference on wednesday, august 10, 2022 at 2:30 p.m. eastern time. management will discuss the company's neuroscience and immuno-oncology programs as well as its artificial intelligence platform used to augment and accelerate the drug candidate discovery and development process. they will also discuss the company's commercial strategy and launch of igalmi™ (dexmedetomidine) sublingual film.
BTAI Ratings Summary
BTAI Quant Ranking